Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026

Astellas Pharma Inc. (TYO: 4503) announced that China’s National Medical Products Administration (NMPA) has accepted...

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Fineline Cube Jul 9, 2026

Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced positive results from its Phase 2 clinical...

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ) has...

Company Drug

Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases

Fineline Cube Jul 9, 2026

Changchun High & New Technology Industry (Group) Inc. (SHE: 000661) announced that China’s National Medical...

Company Medical Device

Johnson & Johnson Secures FDA Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Platform, First Single-Catheter Solution Combining Radiofrequency and Pulsed Field Ablation

Fineline Cube Jul 9, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk

Fineline Cube Jul 9, 2026

AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...

Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026

Xenovector, a pioneering biotechnology company in xenotransplantation, has announced a deep strategic cooperation with Jilin...

Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) and Tigermed Consulting Co., Ltd. (SHE: 300347, HKG:...

Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026

China’s National Health Commission (NHC) has released the National Essential Medicines List (NEML) 2026 Edition,...

Company Medical Device

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Fineline Cube Jul 8, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its proprietary transvenous tricuspid valve replacement system,...

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Fineline Cube Jul 8, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Fineline Cube Jul 8, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its proprietary SHR-4685 has...

Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Fineline Cube Jul 8, 2026

Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ:...

Others

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Fineline Cube Jul 8, 2026

OTR Therapeutics announced a strategic collaboration with LG Chem (KRX: 051910) to jointly accelerate the...

Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Fineline Cube Jul 8, 2026

Hangzhou Qihan Biotech Engineering Life (“Qihan Biotech”) announced that its QT-019C cell injection has received...

Company Drug

Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis

Fineline Cube Jul 8, 2026

Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459)...

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026

Transcenta Holding Limited (HKG: 6628) announced it will return select collaborative products to Eli Lilly...

Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the formal establishment of a Joint Laboratory...

Posts pagination

1 2 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.